Navigation Links
QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
Date:1/23/2008

NEW YORK, Jan. 23 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Monday January 28, 2008 Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) will replace MGI Pharma, Inc. (Nasdaq: MOGN) in the HealthShares(TM) Composite Index. MGI Pharma is being acquired by Eisai Pharma of Japan (Tokyo, TSE:4523).

Eisai Pharma will replace MGI Pharma in the HealthShares(TM) Cancer Index, and Dr. Reddy's Laboratories, Ltd (NYSE: RDY) will replace MGI Pharma in the HealthShares(TM) Neuroscience Index.

The Composite Index consists of the 80 largest companies by market capitalization that are engaged in healthcare, life sciences and/or biotechnology that are part of the 20 Composite eligible Indexes.

Companies included in the HealthShares(TM) Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers. They generally include those with substantial revenues and significant research and development programs.

Companies included in the HealthShares(TM) Neuroscience Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of neurological and psychiatric disorders including, but not limited to, Alzheimer's, Parkinson's, Huntington's, schizophrenia, anxiety, depression, epilepsy, pain and sleep disorders.

The weightings for Regeneron Pharmaceuticals in the HealthShares(TM) Composite Index, Eisai Pharma in the HealthShares(TM) Cancer Index and Dr. Reddy's Laboratories, Ltd. in the HealthShares(TM) Neuroscience Index will be identical to those of companies being removed from their indexes on the effective date.

About QED International Associates

QEDI International, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at http://www.qedinternational.com


'/>"/>
SOURCE QED International Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tasker Products to Showcase Tasker Blue at International Poultry Expo
2. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
3. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
4. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Carbon offset warning from international team of scientists
6. Palomar and Q-MED AB Enter Into International Distribution Agreement
7. International Association of Fire Fighters (IAFF) Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO-Oximetry
8. International team identifies 480 genes that control human cell division
9. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
10. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
11. Baxter International Fourth Quarter 2007 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Md. , March 27, 2017  The ... billion for 2016, according to a new report ... medical lab testing is performed to evaluate disease ... individual therapy, among other reasons.  The healthcare market ... Market , provides an overview of the ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... method to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the ... lead to new and improved ways of treating coronary artery disease (CAD). Lam ...
(Date:3/24/2017)... March 24, 2017 MiMedx Group, Inc. (NASDAQ: ... human placental tissue allografts and patent-protected processes to develop ... of healthcare, announced today  that it will present at ... , NY.  Parker H. "Pete" Petit, Chairman and ... Christopher M. Cashman , EVP and Chief Commercialization ...
(Date:3/24/2017)... 2017 On Thursday, March 23, ... 5,817.69, down 0.07%; the Dow Jones Industrial Average edged ... 500 closed at 2,345.96, marginally dropping 0.11%. US markets ... green, 4 sectors finished in red, and 1 sector ... initiated reports coverage on the following Biotechnology equities: BioDelivery ...
Breaking Biology Technology:
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
Breaking Biology News(10 mins):